Pharmacy benefit manager Express Scripts and Walgreens Boots Alliance, Inc, have announced that they will expand their group purchasing efforts to include specialty drugs, including biologics and biosimilars.
Pharmacy benefit manager Express Scripts and Walgreens Boots Alliance, Inc, have announced that they will expand their group purchasing efforts to include specialty drugs, including biologics and biosimilars. The companies will use ValoremRx Specialty Solutions to source specialty drugs, which the companies say will simplify the supply chain and lead to lower drug costs.
“Specialty medications represent the most costly and complex drugs. By expanding our efforts with Walgreens Boots Alliance, we will improve our supply chain and ultimately make the use of these medicines, including biosimilars, more affordable and accessible for our patients and clients,” said Express Scripts president and CEO Tim Wentworth in a statement.
Walgreens Boots Alliance’s Co-COO, Alex Gourlay, added, “As prescription drug needs evolve and specialty medications are prescribed more often, we continue to look for new solutions that will help our patients get the medications they need at an affordable price.”
Specialty medicines have been a growing concern for Express Scripts, which in 2017 released a report that said that 0.3% of Express Scripts members accounted for 21.3% of total pharmacy costs and that the number of members who had annual medication costs of $50,000 or more in 2016 was 35% higher than in 2014. Among those with $50,000 or more in prescription drug costs in 2016, more than 25% of costs were for specialty drugs with oncology indications, followed by those treating multiple sclerosis, inflammatory conditions, and hepatitis C.
The PBM has said that using biosimilars of bevacizumab, epoetin alfa, trastuzumab, adalimumab, interferon alfa-2a, pegfilgrastim, peginterferon alfa-2b, rituximab, infliximab, and filgrastim could potentially save $250 billion. In its 2018 preferred national formulary, Express Scripts has since signaled a push toward biosimilars, namely in excluding the name-brand Neupogen (filgrastim) in favor of the follow-on Granix or the biosimilar Zarxio.
Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan
June 17th 2025Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, and Samsung Bioepis enters a strategic agreement with NIPRO Corporation in Japan.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships
May 29th 2025The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple sclerosis, while 2 other companies expand their biosimilar partnership to include more products.
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.